- About Us
Description of a radioassay to measure folic acid and folate binding proteins (in use today).
Isolation and characterization of an abnormal vitamin B12 binding protein produced by liver cancer.
The SWCRF is founded with funds donated by fashion executive Irving Alpert. From left: Barry Finn, Shelly Finn, Miriam Alpert, Dr. Samuel Waxman, Marion Waxman and Irving Alpert.
Demonstration that leukemia cells can be made to undergo differentiation and gain a normal function that became the basis for differentiation therapy.
Demonstration that a folic acid derivative can improve the clinical efficacy of a chemotherapeutic agent in the treatment of colon cancer, which is still in use today.
Collaboration with the Shanghai Second Medical University and Shanghai Institute of Hematology begins.
We reported on the principles for combing differentiation agents in the treatment of cancer.
Organized the first of 14 Conferences on Differentiation Therapy of Cancer.
Design of combination cytotoxic-differentiation therapy.
Differentiation therapy with retinoic acid resulted in complete remission in patients with promyelocytic leukemia, a treatment still in use today.
Demonstration that breast cancer cells can be made to undergo differentiation in the laboratory.
Demonstration of a mechanism which blocks gene expression and causes leukemia.
Cloning of the PLZF gene and mechanism whereby it blocks the response to retinoic acid treatment of acute promyelocytic leukemia.
Identification of agents that can enhance retinoic acid differentiation therapy.
Samuel Waxman receives Honorary Professorship from the Shanghai Second Medical University and the Magnolia Award from the Shanghai Municipal Government for contributions to the treatment of leukemia.
Demonstration that breast cancer is associated with abnormal vitamin A gene function.
Use of arsenic trioxide as a targeted treatment for acute promyelocytic leukemia, a procedure that is still in use today.
Tumor dormancy is created in the laboratory by a single gene insertion.
Laboratory reports that combining a chemotherapeutic agent with a differentiation agent is effective in colon cancer. Subsequent clinical trials demonstrate feasibility and safety.
Laboratory reports that arsenic trioxide is effective in malignant lymphoma.
SWCRF launches an expanded research initiative.
Laboratory report demonstrating the effectiveness of a combination cytotoxic differentiation therapy with interferon and a non-steroidal anti-inflammatory agent blocks growth of human colon carcinoma cells.
Identification of a differentiation associated gene, which can be used as gene therapy in patients with lung cancer.
Laboratory demonstration that arsenic trioxide is effective in multiple myeloma and can be enhanced by vitamin C, and initiated several clinical trials.
Tested a model to predict whether blocking EGF receptor may be clinically useful.
The Shanghai/ SWCRF Co-PI program launches.
The SWCRF launched programs on abnormal gene expression in blood malignancies, tumors dormancy, and liver cancer.
Designed cancer-specific targets in lung cancer and initiated a clinical trial.
Demonstration that a specific mutation in lung cancer may predict whether blocking EGF receptor may be helpful to treat lung cancer (will be done in all lung cancers in the near future).
Funding for scientists to develop drugs that block a gene defect in 80% of patients with melanoma.
Design of small compounds that block a specific site in lymphoma cells as a potential treatment.
Genetically engineered to block in vitamin A metabolism in a mouse, results in an increased incidence of breast cancer. Vitamin A derivatives will be used to interfere with this process.
Discovery of a switch that allows cancer cells to become both dormant and chemotherapy resistant.
Discovery of the hPNPase gene, a regulator of normal and cancer cell differentiation and senescence.
Discovery of a novel target for Bortezomib, useful in treating lymphoma and breast cancer.
NQ01 serves as a gatekeeper for protein removal, a new cancer-specific target.
Report that inhibitors that block NF-kB enhance the effect of chemotherapy and radiation.
Discovery of a new distinct class of EGFR inhibitors effective in lung cancer.
Discovery that arsenic trioxide may be effective in treating other forms of leukemia and myelodysplastic syndrome.
Discovery of inhibitors that selectively kill melanoma cells with the B-Raf mutation.
Report of a set of genes that separates pre-liver cancer from liver cancer.
Demonstration that combining arsenic with Gleevac is more effective in treating the aggressive phase of chronic myelogenous leukemia.
Development and implementation of a window of opportunity trial platform to validate in human cancers the same pathways uncovered in the laboratory.
Designed and implemented a robotic-based platform resource for linking cancer mutations to response or resistance to novel anti-cancer drugs.
Developed a therapy to block metastasis formation.
Collaborating SWCRF researchers discover mutated enzymes that cause Intrahepatic cholangiocarcinoma, a deadly liver cancer.
SWCRF scientists win international joint grant for AML research from Israel and China.
Identification of two avermectins - compounds with insecticidal properties - that may serve as therapeutic agents against Triple-Negative Breast Cancer cells.
SWCRF researchers identify a microRNA that promotes the onset of CML and Down Syndrome AML.
SWCRF celebrates awarding nearly $90 million in cancer research grants to 200 scientists throughout the world over 40 years.
The Partnership for Aging and Cancer Research Program launches as a two-year collaboration with the SWCRF, National Cancer Institute, and National Institute on Aging.